In comments posted in response to the Trump administration’s pharma tariff investigation, companies and industry groups ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

The overturning of the FDA’s lab-developed tests rule is just the tip of the iceberg. With the loss of Chevron deference, ...

With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug ...

Actym Therapeutics has strengthened its IP portfolio with two newly issued patents covering its novel STACT™ biological ...

In 2018, the FDA began an investigation into nitrosamine impurities in drugs that led to high-profile recalls for heartburn ...

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...

Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

The medium-sized biopharma is showing off new results from dordaviprone and Zepzelca, both of which were acquired through ...

Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...